HUTCHMED (China) Ltd — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020; this is an annual report, not a standalone Q4 filing. The company reports in U.S. dollars under U.S. GAAP. It is a commercial-stage biopharmaceutical business with Oncology/Immunology operations and Other Ventures, principally China-focused pharmaceutical and consumer-health businesses.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $228.0 million | $204.9 million |
| Cost of revenue | $188.5 million | $160.2 million |
| Gross profit and margin | $39.5 million; 17.3% | $44.7 million; 21.8% |
| Research and development expense | $174.8 million | $138.2 million |
| Net loss attributable to the company | $125.7 million | $106.0 million |
| Net cash used in operating activities | $62.1 million | $80.9 million |
| Cash and cash equivalents | $235.6 million | $121.2 million |
| Short-term investments | $199.5 million | $96.0 million |
At year-end, cash and short-term investments totaled $435.2 million. Bank borrowings were $26.9 million, with $69.4 million of undrawn facilities. Management said available funds, expected operating cash flows, joint-venture dividends and facilities should cover operating expenses, debt service and capital expenditure for at least 12 months. The company reported no dividend plan.
Changes versus FY2019
- Revenue rose 11.3%. Oncology/Immunology revenue increased to $30.2 million, including $20.0 million related to Elunate (fruquintinib), versus $10.8 million in FY2019. Eli Lilly reported Elunate in-market sales of $33.7 million, up 91.5%.
- Other Ventures revenue increased 11.0% to $197.8 million, led by higher prescription-drug sales; consumer-health revenue declined.
- Cost of revenue grew faster than sales, reflecting a greater mix of lower-margin Hutchison Sinopharm products; gross margin fell to 17.3% from 21.8%.
- R&D expense increased 26.5%, reflecting expanded clinical programs, U.S. activity and staffing. The company’s net loss attributable to it widened to $125.7 million.
- Operating cash use improved by $18.8 million, helped by $86.7 million in dividends received from joint ventures, compared with $28.1 million in FY2019.
- Financing cash flow included approximately $310 million of net proceeds from the 2020 follow-on offering and private placements.
Outlook, commentary and risks
- Surufatinib was approved in China in December 2020 for non-pancreatic NET and launched in January 2021. Its U.S. rolling NDA submission began in December 2020; management planned to complete it in the first half of 2021, subject to FDA review. A potential U.S. launch was anticipated for late 2021 or early 2022, if approved.
- Savolitinib’s China NDA for MET-altered NSCLC was under review. Fruquintinib’s global Phase III FRESCO-2 study began in 2020; results and regulatory outcomes remain uncertain.
- The company expects R&D and commercialization spending to rise. Management said additional financing may be needed to fund planned clinical development; equity financing could dilute shareholders.
- A one-time land-return gain at Hutchison Baiyunshan materially boosted FY2020 equity-method earnings: the JV recorded an $84.7 million gain, of which $36.0 million was attributable to HUTCHMED. The remaining compensation was expected in 2021 and part was conditional on government confirmation.
- Key risks include clinical-trial and regulatory failure or delay, competition and reimbursement/pricing pressure, COVID-19-related disruption, reliance on partners and sole-source active-ingredient suppliers, China operating and foreign-exchange restrictions, and dependence on joint-venture dividends. The filing also highlights the risk that PCAOB inspection limitations could threaten Nasdaq listing if applicable requirements are not met.
- The company reported effective disclosure controls and internal control over financial reporting. It disclosed no material pending litigation against the company, while noting a continuing dispute with Luye over termination of a Seroquel distribution agreement.
Most important facts to verify
- Whether surufatinib’s U.S. NDA was completed and accepted, and the subsequent regulatory and launch timeline.
- Elunate’s continued sales growth and the economics of the expanded Eli Lilly commercialization arrangement, including sales-target conditions.
- Whether operating cash burn, R&D spending and joint-venture dividends support management’s stated liquidity runway.
- The timing and receipt of remaining Baiyunshan land compensation, including the amount subject to government confirmation.
- Clinical and regulatory progress for savolitinib, fruquintinib and other pipeline candidates, plus manufacturing and API supply capacity.